Testing, monitoring, and clinical data resources
T1D testing and monitoring handbook
Discover the testing process and monitoring guidance for patients identified as at-risk of progression to Stage 3 autoimmune T1D.
Download brochureDosing resources
Dosing and administration guide for TZIELD
Guide to dosing, preparation, and administration of TZIELD.
Download guideHelpful links
2024 ISPAD Clinical Practice Consensus Guidelines
The only comprehensive set of clinical recommendations for children, adolescents, and young adults with diabetes from the International Society for Pediatric and Adolescent Diabetes (ISPAD).
BSPED Guidelines
Guidelines commissioned and developed by the British Society for Paediatric Endocrinology and Diabetes (BSPED).
ELSA Study
The ELSA Study is screening children in the United Kingdom (UK) aged 3–13 years to assess the risk of developing T1D.
T1DRA Study
The T1DRA Study is screening UK general population adults aged 18–70 to assess the risk of developing T1D.
By following the links above, you will be directed to independent websites which Sanofi has no control over. Sanofi accepts no responsibility for the content or availability of the websites.
Get in Touch with Us
Questions? Leave your details and we'll reach out to you at your preferred time.
Get in touchINDICATION: TZIELD is indicated to delay the onset of Stage 3 T1D in adult and paediatric patients 8 years of age and older with Stage 2 T1D.1
BSPED, British Society for Paediatric Endocrinology and Diabetes; ISPAD, International Society for Pediatric and Adolescent Diabetes; T1D, Type 1 diabetes; UK, United Kingdom.
- TZIELD® (teplizumab) UK Summary of Product Characteristics. 2025.
MAT-XU-2500769 (v1.0) | November 2025